Nattapong TidwongPreecha MontakantikulWeerawat ManosuthiMahidol UniversityChiang Mai UniversityBamrasnaradura Infectious Diseases Institute2020-06-022020-06-022020-01-01Pharmaceutical Sciences Asia. Vol.47, No.2 (2020), 97-10325868470258681952-s2.0-85085214601https://repository.li.mahidol.ac.th/handle/20.500.14594/56310© Faculty of Pharmacy, Mahidol University (Thailand) 2020. As of March 22, 2020, a total of 292,142 confirmed coronavirus disease 2019 (COVID-19) cases have been reported globally. Although there are currently no specific antiviral agents but all coronaviruses shared similar key elements of target for currently approved antiviral or new drug development. Several agents might be considered as a possible treatment based on the efficacy in SARS and MERS.Mahidol UniversityMedicinePharmacology, Toxicology and PharmaceuticsReviewSCOPUS10.29090/psa.2020.02.020.0026